Sustained aquaretic effect of the V 2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention

British Journal of Pharmacology

Volumn 146, Issue 5, 2005, Pages 654-661

  Ros, Josefa ^a   Fernández Varo, Guillermo ^a   Mũoz Luque, Javier ^a   Arroyo, Vicente ^a   Rodés, Juan ^a   Gunnet, Joseph W ^b   Demarest, Keith T ^b   Jiménez, Wladimiro ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Aquaretics; AVP receptor antagonist; Cirrhosis; Hyponatremia; Water retention

Indexed keywords

CARBON TETRACHLORIDE; RWJ 351647; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE CLEARANCE; DIURESIS; DRUG BLOOD LEVEL; DRUG EFFECT; HEMODYNAMIC MONITORING; KIDNEY DISEASE; LIVER CIRRHOSIS; MALE; NONHUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; RAT; SODIUM EXCRETION; URINARY EXCRETION; URINE OSMOLALITY; URINE VOLUME; WATER RETENTION;

ANIMALS; ASCITES; BENZODIAZEPINES; BODY WATER; DIURETICS; HORMONES; KIDNEY; LIVER CIRRHOSIS; MALE; OSMOLAR CONCENTRATION; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; SODIUM;

EID: 27644574116     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706375     Document Type: Article

References (30)

1. 2 receptors. J. Med. Chem., 41, 2442-2444.
2. ALLISON, N.L., ALBRIGHTSON-WINSLOW, C.R., BROOKS, D.P., STASSEN, F.L., HUFFMAN, W.F., STOTE, R.M. & KINTER, L.B. (1988). Species heterogeneity and antidiuretic hormone antagonists: what are the predictors?. In: Vasopressin: Cellular and Integrative Functions, ed. Cowley, A.W., Liard, J.F. & Ausiello, D.A. pp. 207-214. New York, NY: Raven Press Ltd.
3. ARROYO, V., CLÀRIA, J., SALÓ, J. & JIMÉNEZ, W. (1994). Antidiuretic hormone and pathogenesis of water retention in cirrhosis with ascites. Semin. Liver Dis., 14, 44-58.
4. ARROYO, V. & JIMÉNEZ, W. (2003). Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology, 37, 13-15.
5. BELLISANT, E., DENOLLE, T., SINNASSAMY, P., BICHET, D.G., GIUDICELLI, J.F., LECOZ, F., GANDON, J.M. & ALLAIN, H. (1996). Systemic and regional hemodynamic and biological effects of a new κ-opioid agonist, niravoline, in healthy volunteers. J. Pharmacol. Exp. Ther., 278, 232-242.
6. BOSCH-MARCÉ, M., JIMÉNEZ, W., ANGELI, P., LEIVAS, A., CLÀRIA, J., GRAZIOTTO, A., ARROYO, V., RIVERA, F. & RODÉS, J. (1995). Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology, 109, 217-223.
7. BOSCH-MARCE, M., POO, J.L., JIMÉNEZ, W., BORDAS, N., LEIVAS, A., MORALES-RUIZ, M., MUÑOZ, R.M., PÉREZ, M., ARROYO, V., RIVERA, F. & RODÉS, J. (1999). Comparison between two aquaretic drugs (niravoline vs OPC-31260) in cirrhotic rats with ascites and water retention. J. Pharmacol. Exp. Ther., 289, 194-201.
8. CAMPS, J., SOLÁ, J., ARROYO, V., PÉREZ-AYUSO, R.M., GAYA, J., RIVERA, F. & RODÉS, J. (1987). Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology, 93, 498-505.
9. CLÀRIA, J. & JIMÉNEZ, W. (1999). Renal dysfunction and ascites in carbon-tetrachloride-induced cirrhosis in rats. In: Ascites and Renal Dysfunction in Liver Disease. Pathogenesis Diagnosis and Treatment, ed. Arroyo, V., Ginès, P., Rodés, J., Schrier, R.W., pp. 379-396. Blackwell: Science Inc.
10. CLÀRIA, J., JIMÉNEZ, W., ARROYO, V., LA VILLA, G., LÓPEZ, C., ASBERT, M., CASTRO, A., GAYA, J., RIVERA, F. & RODÉS, J. (1991). Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology, 100, 494-501.
11. 2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J. Hepatol., 38, 755-761.
12. GERBES, A.L., GÜLBERG, V., GINÈS, P., DECAUX, G., GROSS, P., GANDJINI, H., DJIAN, J. & The VPA Study Group (2003). Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology, 124, 933-939.
13. GUYADER, D., PATAT, A., ELLIS-GROSSE, E.J. & ORCZYK, G.P. (2002). Pharmacodynamic effect of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology, 36, 1197-1205.
14. HAMON, G. & JOUQUEY, S. (1990). Kappa agonists and vasopressin secretion. Horm. Res., 34, 129-132.
15. JARD, S. (1988). Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int., 34, S38-S42.
16. JIMÉNEZ, W., MARTINEZ-PARDO, A., ARROYO, V., BRUIX, J., RIMOLA, A., GAYA, J., RIVERA, F. & RODÉS, J. (1985). Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology, 5, 245-250.
17. 2-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J. Pharmacol. Exp. Ther., 295, 83-90.
18. LEE, C.R., WATKINS, M.L., PETTERSON, J.H., GATTIS, W., O'CONNOR, C.M., GHEORGHIADE, M. & ADAMS, K.F. (2003). Vasopressin: a new target for the treatment of heart failure. Am. Heart J., 146, 9-18.
19. MANNING, M., PRZYBYLSKI, J.P., OLMA, A., KLIS, W.A., KRUSZYNSKI, M., WO, N.C., PELTON, G.H. & SAWYER, W.H. (1987). No requirement of cyclic conformation of antagonists in binding to vasopressin receptors. Nature, 329, 839-840.
20. MATTHEWS, J.M., HOEKSTRA, W.J., DYATKIN, A.B., HECKER, L.R., HLASTA, D.J., POULTER, B.L., ANDRADE-GORDON, P., DE GARAVILLA, L., DEMAREST, K.T., ERICSON, E., GUNNET, J.W., HAGEMAN, W., LOOK, R., MOORE, J.B., REYNOLDS, C.H. & MARYANOFF, B.E. (2004). Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates. Bioorg. Med. Chem. Let., 14, 2747-2752.
21. NIELSEN, S., FROKIAER, I., MARPLES, D., KWON, T.H., AGRE, P. & KNEPPER, M.A. (2002). Aquaporins in the kidney: from molecules to medicine. Physiol. Rev., 82, 205-244.
22. 2 and kallikrein in hyponatremic cirrhosis. Nephron, 36, 30-37.
23. SAWYER, W.H., PANG, P.K.T., SETO, J., MCENROE, M., LAMMEK, B. & MANNING, M. (1981). Vasopressin analogues that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science (Washington, DC), 312, 49-51.
24. 2 receptor antagonist. Vusopressin Oxytocin, 449, 427-438.
25. SLIZGI, G.R. & LUDENS, J.H. (1982). Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J. Pharmacol. Exp. Ther., 220, 585-591.
26. 2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther., 282, 301-308.
27. 1A vasopressin receptor antagonist, in patients with advanced heart failure. Circulation, 104, 2417-2423.
28. WONG, F., BLEI, A.T., BLENDIS, L.M., THULUVATH, P.J. & for The North American VPA-985 Study Group (2003). A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter randomized placebo-controlled trial. Hepatology, 37, 182-191.
29. 2 receptor antagonists. Cardiovasc. Res., 51, 391-402.
30. 2 receptor antagonist. Br. J. Pharmacol., 105, 787-791.